Aucta is developing products in CNS, in particular, epilepsy, Dermatology and Pediatrics to bring new therapeutics that are not on the market to patients, in order to fulfill the unmet medical needs. To support this, the company has three distinct proprietary technology platforms: Auc-Ped, Auc-Trol and Auc-Derm.

We continuously evaluate and evolve our technology toolbox. We may initiate new areas of research based on new proprietary technologies that have platform characteristics and can produce a line of products.